Here's what I am seeing today: speculative buying based on the webinar announcement for a potential pump and dump going into Thursday.
Only thing that will change the SP med-long term is a collab with $ upfront or milestone payments involved.
So worst case scenario is that the HSV-2 Vax is a bomb. Right? In that case, we'd - I hope - see AHZ divest itself of the Immunotherapies division immediately making the company CF+ by a large margin in the next 6 months easy.
If not a bomb then we'd have to see a partnership/collab with the aforementioned up fronts/milestone to justify keep running it.
So we need decisive action on this now. If a CR is proffered to fund the operational costs of the Vax program I will be very very disappointed.
Ann: HSV-2 Phase IIa Results Investor Webinar, page-128
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |